Skip to main content

Idorsia enters collaboration with Viatris

| News

Idorsia enters collaboration with Viatris


The biotech company Idorsia from the canton of Basel-Landschaft and the North American pharmaceutical company Viatris are collaborating on the development of two of Idorsia's Phase 3 drugs. Idorsia will receive an upfront payment of 350 million dollars as well as milestone payments.

Idorsia headquarters in Allschwil in the canton of Basel-Landschaft (image: Jean Jacques Schaffner)

The listed biotech company Idorsia and Viatris have agreed on a global collaboration for the further development of the two Phase 3 drugs Selatogrel and Cenerimod. According to a statement, Idorsia will receive an upfront payment of 350 million dollars as well as milestone payments and royalties on annual net sales.

A joint committee will oversee the development of the ongoing Phase 3 programs. Idorsia is expected to contribute up to 200 million dollars over the next three years. Viatris, based in the US state of Pennsylvania, will receive the global marketing rights for Selatogrel and Cenerimod. Cenerimod excludes some Asian countries.

Potential blockbuster assets

Selatogrel is an emergency medication for acute myocardial infarction. It can be self-administered via an autoinjector by people with a respective medical history. The U.S. Food and Drug Administration (FDA) is prioritizing this program because of its importance. Cenerimod represents a novel approach to the treatment of systemic lupus erythematosus and is the result of 20 years of research by Idorsia. Viatris CEO Scott A. Smith describes the two medications as “potential blockbuster assets”.

According to Idorsia Chief Financial Officer André C. Muller, “the upfront payment of USD 350 million gives us much needed liquidity. We’ve repeatedly explained that we have many balls in the air, we’ve now caught the first one and continue to work on others.”

In this regard, Idorsia is negotiating with Viatris for other pipeline products. Decisions by the FDA and the European Medicines Agency regarding the hypertension drug Aprocitentan and the novel sleep aid QUIVIQ (daridorexant) are also expected shortly.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.